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Abstract
Background Over the last 50 years, clinical trials of novel inter-
ventions for acute heart failure (AHF) have, with few exceptions,
been neutral or shown harm. We hypothesize that this might be
related to a differential response to pharmacological therapy.
Methods We studied the magnitude of treatment effect of
rolofylline across clinical characteristics and plasma bio-
markers in 2033 AHF patients and derived a biomarker-
based responder sum score model. Treatment response was
survival from all-cause mortality through day 180.
Results In the overall study population, rolofylline had no
effect on mortality (HR 1.03, 95% CI 0.82–1.28, p = 0.808).
We found no treatment interaction across clinical characteris-
tics, but we found interactions between several biomarkers
and rolofylline. The biomarker-based sum scoremodel includ-
ed TNF-R1α, ST2, WAP four-disulfide core domain protein
HE4 (WAP-4C), and total cholesterol, and the score ranged
between 0 and 4. In patients with score 4 (those with increased
TNF-R1α, ST2, WAP-4C, and low total cholesterol), treat-
ment with rolofylline was beneficial (HR 0.61, 95% CI
0.40–0.92, p = 0.019). In patients with score 0, treatment with
rolofylline was harmful (HR 5.52, 95% CI 1.68–18.13,
p = 0.005; treatment by score interaction p < 0.001). Internal
validation estimated similar hazard ratio estimates (0 points:
HR 5.56, 95% CI 5.27–7–5.87; 1 point: HR 1.31, 95% CI
1.25–1.33; 2 points: HR 0.75, 95% CI 0.74–0.76; 3 points:
HR 1.13, 95% CI 1.11–1.15; 4 points, HR 0.61, 95% CI 0.61–
0.62) compared to the original data.
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Conclusion Biomarkers are superior to clinical characteristics
to study treatment heterogeneity in acute heart failure.
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Introduction
Acute heart failure is one of the leading causes of hospitaliza-
tion among patients ≥65 years and carries a dismal prognosis
and high economic burden [1, 2]. Treatment of acute heart
failure remains a therapeutic challenge as current guideline
recommendations are based on smaller, nonrandomized trials
and expert opinion [2]. Many potential interventions for acute
heart failure have been studied, but most of them have failed to
improve prognosis and none of them have entered guideline
recommendations [2–8]. Several reasons have been ad-
dressed: the wrong drugs might have been studied, or the
wrong study designs might have been used. We hypothesize
that one of the most important explanations is likely the het-
erogeneity of patients with acute heart failure. In clinical trials,
treatment arms are analyzed as a whole and there seems to be
some consensus that heterogeneity of the relative treatment
effect is rare. However, in a trial including relatively unselect-
ed heart failure patients, differential responses to treatment are
to be expected. The wide variety in the underlying pathophys-
iological mechanisms and clinical presentations in acute heart
failure challenges selection of an appropriate study population
and, intuitively, hampers a universal treatment that fits all
patients. Based on these factors, acute heart failure might hold
a great potential for precision medicine. Understanding differ-
ences in treatment response is imperative to customize thera-
py. Subgroup analyses are thus necessary to identify potential
interactions between underlying pathophysiologies and treat-
ment effect. However, conventional subgroup analysis based
on clinical characteristics often failed to demonstrate any in-
teraction effect with treatment. As plasma biomarkers may
characterize individual involved pathophysiological path-
ways, these markers can be particularly useful to study varia-
tion in drug response profiles. In the present study, we propose
a novel method to use a large panel of established and novel
emerging biomarkers to distinguish responders from nonre-
sponders to pharmacological therapy in acute heart failure.
Methods
Patient Population
We investigated patients enrolled in the Placebo-controlled
Randomized Study of Selective A1 Adenosine Receptor
Antagonist Rolofylline for Patients Hospitalized with Acute
Decompensated Heart Failure and Volume Overload to
Assess Treatment Effect on Congestion and Renal Function
(PROTECT) trial [7, 9]. The design and main results of the
study have been published elsewhere [7, 9]. Between
May 2007 and January 2009, 2033 acute heart failure patients
were randomized to receive 30 mg rolofylline or placebo ad-
ministered as a daily 4 h infusion for 3 days in a 2:1 ratio.
Briefly, eligible patients were male or female, ≥18 years of
age, hospitalized for signs and symptoms of acute heart failure,
defined as persistent dyspnea at rest or minimal exertion and
fluid overload requiring intravenous loop-diuretic therapy, with
impaired renal function (estimated creatinine clearance of 20–
80 mL/min calculated by the Cockcroft-Gault equation
(corrected for height in edematous or obese patients
≥100 kg)) and elevated natriuretic peptide levels (brain natri-
uretic peptide (BNP) or N-terminal pro-BNP levels ≥500 or
≥2000 pg/mL, respectively). Key exclusion criteria included
systolic blood pressure <90 or ≥160 mmHg, acute coronary
syndrome and treatment with positive inotropic agents, vaso-
pressors or vasodilatators (with the exception of intravenous
nitrates), ultrafiltration, hemofiltration, dialysis, or mechanical
support. The PROTECT trial conformed to the Declaration of
Helsinki, local ethics committees at each participating center
approved the study, and all participating patients provided writ-
ten informed consent. Demographic, clinical, and biochemical
variables of interest were collected within the framework of the
PROTECT study. The PROTECT trial was registered at
ClinicalTrials.gov: NCT00328692 and NCT00354458.
Biochemical Analyses
Venous blood sampling was performed daily through day 6
or discharge and day 7 and 14 with K3EDTA Vacutainers.
For the present analysis, we analyzed baseline values. We
retrospectively used a panel of 48 markers that were already
available and published before [10]. These biomarkers were
a combination of routine laboratory markers from local lab-
oratories, as well as centrally measured biomarkers, and
there was no specific selection for the present study. The
following biomarkers were available: albumin, alanine trans-
aminase, aspartate transaminase, bicarbonate, blood urea ni-
trogen (BUN), chloride, creatinine, glucose, hemoglobin,
platelet count, potassium, red blood cell count, sodium, total
cholesterol, triglycerides, uric acid, and white blood cell
count were measured in a central laboratory (ICON
Laboratories, Farmingdale, NY). Remaining plasma was
then separated from blood as soon as possible by centrifu-
gation at 1500×g for 10 min and stored at −80 °C. Thirty-
one biomarkers of different biological domains (inflamma-
tion, oxidative stress, remodeling, cardiomyocyte stretch, an-
giogenesis, atherosclerosis, renal function) were determined
immediately after defrosting plasma. The following
282 Cardiovasc Drugs Ther (2017) 31:281–293
biomarkers were determined: galectin-3, myeloperoxidase,
and neutrophil gelatinase-associated lipocalin were measured
using sandwich enzyme-linked immonsorbent assays
(ELISA) on a microtiter plate; angiogenin and C-reactive
protein were measured using competitive ELISAs on a
Luminex® platform; D-dimer, endothelial cell-selective ad-
hesion molecule (ESAM), growth differentiation factor 15
(GDF-15), lymphotoxin beta receptor, mesothelin,
neuropilin, N-terminal pro C-type natriuretic peptide, osteo-
pontin, procalcitonin, pentraxin-3, periostin, polymeric im-
munoglobulin receptor, pro-adrenomedullin, prosaposin B,
receptor for advanced glycation endproducts, soluble ST-2
(ST2), syndecan-1, tumor necrosis factor alpha receptor 1
(TNF-R1α), tumor necrosis factor receptor superfamily
member, vascular endothelial growth receptor 1, and WAP
four-disulfide core domain protein HE4 (WAP-4C) were
measured using sandwich ELISAs on a Luminex® platform
(Alere™ Inc., San Diego, CA, USA). Immunoassays for
procalcitonin, proADM, galectin-3, and ST2 were developed
by Alere™. These research assays have not been standard-
ized to the commercialized assays used in research or in
clinical use. Further, the extent to which each Alere™ assay
correlates with the commercial assay is not fully character-
ized. Kidney Injury Molecule 1, BNP, interleukin-6,
endothelin-1, and cardiac-specific Troponin I were measured
in frozen plasma samples using highly sensitive single mol-
ecule counting (SMC™) technology (RUO, Erenna®
Immunoassay System, Singulex Inc., Alameda, CA, USA).
Statistical Analysis
Continuous variables are summarized as mean ± standard de-
viation if normally distributed or median and interquartile
range if nonnormally distributed. Categorical variables are
reported as percentages of observations. Analysis of variance,
Student’s t test, Chi-square test, and Mann-Whitney U test
were used as appropriate for group comparisons. We included
all 2033 patients enrolled in the PROTECT trial for the present
analysis. Patients with missing baseline values of the covariate
of interest were excluded from the analysis of the subgroup of
interest. A full, complete 48-biomarker panel was obtained for
1266 patients. Treatment response was defined as survival
from all-cause mortality through day 180. We explored treat-
ment heterogeneity across clinical characteristics by examin-
ing forest plots. Subgroups based on clinical characteristics
were defined by median (if continuous) or by category (if
categorical). Interaction was estimated by Cox proportional
hazard analysis using an interaction term. We explored treat-
ment heterogeneity across the levels of biomarkers using for-
est plots. Subgroups based on biomarkers were defined by
median of the biomarker of interest. Also, to explore treatment
heterogeneity across the spectrum of the biomarkers and to
establish a clinical relevant cut-point, we also studied
differential response across the spectrum of biomarkers using
the subpopulation treatment effect pattern plot (STEPP) [11,
12]. A p value of ≤0.05 was considered statistically signifi-
cant. All analyses were performed using R: A Language and
Environment for Statistical Computing, version 3.1.1 (R
Foundation for Statistical Computing, Vienna, Austria). The
stepp package was used to perform STEPP analyses.
Subpopulation Treatment Effect Pattern Plot
STEPP is a novel graphical method and allows exploring differ-
ential treatment effect across the continuum of a biomarker [11,
12]. STEPP divides the overall study population into overlap-
ping subgroups defined by the median value. Treatment effect
will be assessed in each subpopulation. By creating overlapping
subpopulations, STEPP is a more accurate, robust, and reliable
statistical method to explore treatment heterogeneity across sub-
groups. The advantage of this approach compared with tradi-
tional analysis is that STEPP greatly increases the precision of
the estimated treatment effect, improves statistical power to de-
tect treatment effect heterogeneity, and reduces the chance of
false-negative discovery. In addition, STEPP allows studying
differential response across the continuum of a variable. In our
study, overlapping subgroups were generated so that the maxi-
mum size of each subpopulation was set between 150 and 300
patients, while the number of patients belonging to adjacent
subgroups was 50–150. STEPP depicts estimates of absolute
risk and relative risk across subpopulations with increasing me-
dian concentration levels of the biomarker of interest. STEPP
generates three plots: effect estimated of the two treatments
against the median of each subpopulation, effect differences of
the two treatments in absolute scale against the median of each
subpopulation, and effect ratios of the two treatments in relative
scale against the median of each subpopulation. To evaluate the
statistical significance of observed response differences, permu-
tation tests are performed. In our analysis, the number of permu-
tation tests was set at 2500. To conclude that there is a significant
interactionwith treatment, the plots should show a divergent and
consistent pattern along the continuum of the biomarker.
Sum Score Model
To identify subgroups with distinct response to treatment, we
developed a score model. For this model, we selected bio-
markers only. Because STEPP allowed us to study treatment
heterogeneity across the continuum of a biomarker, we ex-
plored each STEPP plot of the relative treatment effect. Only
biomarkers with both a significant treatment interaction and a
divergent and consistent pattern plot were selected. The
STEPP plot was used to determine clinically relevant cut-
points: the concentration where the STEPP plot demonstrated
a cross-over in relative treatment effect. We created a new
factor variable and divided patients into subgroups according
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Table 1 Baseline characteristics
according to treatment Variable Rolofylline Placebo p value
Number 1313 650
Demographics
Sex (% male) 66.9 (878) 66.6 (433) 0.951
Age (years) 70.1 ± 11.7 70.2 ± 11.5 0.852
BMI (kg/m2) 28.9 ± 6.1 28.7 ± 6.2 0.612
LVEF (%) 32.1 ± 12.7 32.4 ± 13.6 0.709
HFPEF (%) 18.6 (118) 21 (65) 0.447
Systolic blood pressure (mmHg) 124.4 ± 17.5 124.3 ± 17.8 0.911
Diastolic blood pressure (mmHg) 73.7 ± 11.8 74.1 ± 11.9 0.472
Heart rate (beats/min) 80 ± 15.3 80.6 ± 15.7 0.408
Clinical profile
Atrial fibrillation on presentation 38.1 (203) 47.7 (124) 0.012
Orthopnea (%) 95.8 (1242) 96.9 (622) 0.312
Rales (%) 63 (826) 58.3 (378) 0.051
Edema (%) 67.8 (890) 67.4 (438) 0.881
Jugular venous pressure (%) 40.8 (485) 41.4 (242) 0.867
Medical history
Hypertension (%) 80.3 (1054) 77.4 (503) 0.153
Diabetes mellitus (%) 45.2 (593) 46.2 (300) 0.725
Hypercholesterolemia (%) 51.2 (672) 52.1 (338) 0.744
Smoking (%) 21.3 (279) 19 (123) 0.25
Ischemic heart disease (%) 70.4 (923) 67.8 (440) 0.259
Myocardial infarction (%) 51 (668) 46.4 (301) 0.059
PCI (%) 26.4 (343) 25.3 (163) 0.671
CABG (%) 21.2 (276) 21.8 (140) 0.804
Peripheral vascular disease (%) 11.4 (149) 9.6 (62) 0.256
Atrial fibrillation (%) 53.2 (696) 57 (366) 0.125
NYHA class 0.18
I/II 15.8 (208) 19.2 (125)
II 48.9 (642) 46.9 (305)
IV 29.9 (393) 28.9 (188)
ICD therapy (%) 16.1 (212) 15.3 (99) 0.658
CRT therapy (%) 10.2 (134) 9.6 (62) 0.717
Stroke (%) 9 (118) 9.2 (60) 0.926
COPD (%) 19.9 (261) 19.8 (128) 0.983
Prior medication use
ACE inhibitors or ARB (%) 76.2 (1000) 74.6 (485) 0.469
Beta blockers (%) 76.7 (1006) 76.5 (497) 0.961
Mineralocorticoid receptor antagonists (%) 44.6 (585) 43.4 (282) 0.648
Calcium antagonists (%) 15 (196) 10.6 (69) 0.01
Nitrates (%) 26.9 (353) 23.6 (153) 0.126
Digoxin (%) 27.5 (361) 30.3 (197) 0.216
Laboratory values
Creatinine (mg/dL) 1.4 [1.1–1.8] 1.3 [1.1–1.7] 0.135
Creatinine clearance (mL/min) 48.6 [36.4–62.9] 49.8 [37.8–64.9] 0.16
Blood urea nitrogen (mg/dL) 30 [22–41] 29 [22–41] 0.303
Sodium (mmol/L) 140 [137–142] 140 [137–142] 0.265
Potassium (mmol/L) 4.2 [3.9–4.7] 4.2 [3.9–4.6] 0.64
Hemoglobin (g/dL) 12.7 ± 2 12.6 ± 1.9 0.527
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to this cut-point. The new factor variables of biomarkers
showing a significant treatment interaction were entered in a
multivariable Cox regression model. The scores were related
to the values of the predictors; thus, the scores were directly
derived from the regression coefficients, by multiplying by 2
and rounding them. Thus, only biomarkers with a β-coeffi-
cient > 0.25 were included in the final sum score model.
Treatment effect was then estimated for each subgroup of
possible value of the score.
Internal Validation
To test the robustness of our model results, we performed
superpopulation bootstrap with 1000 iterations. We creat-
ed a superpopulation by multiplying each subject ten
times. From the created superpopulation, we sampled
1000 times a resample without replacement with the same
sampling fraction as the original sample (n = 2033). We
tested the treatment effect in each resample and estimates
of hazard ratios and 95% CIs around the variable’s coef-
ficients from each subgroup were compared with those
from the original population.
Results
Baseline characteristics of the subpopulation of patients with
at least one biomarker measured are presented in Table 1.
Mean age of the patients was 70.2 ± 11.6 years and 67% were
male. The majority of patients had ischemic heart disease and
hypertension and used renin-angiotensin-aldosterone system
blockers and/or beta-blockers. Mean left ventricular ejection
fraction was 32.2 ± 13%, and blood pressure was well-
controlled (124.4 ± 17.6/73.9 ± 11.8 mmHg). No pronounced
differences were observed for patient characteristics according
to treatment arm. In the total study population, treatment with
rolofylline did not result in a decreased risk for all-cause death
through day 180 (HR 1.03, 95% CI 0.82–1.28, p = 0.808,
Fig. 1).
Treatment Heterogeneity of Rolofylline
Clinical Characteristics
Subgroup analyses across clinical characteristics are presented
in Fig. 2a. We found no interactions between treatment and
age, sex, and left ventricular ejection fraction (LVEF). Also,
Fig. 1 Kaplan-Meier curve for
180-day all-cause mortality in the
overall study population
Table 1 (continued)
Variable Rolofylline Placebo p value
Anemia (%) 42 (487) 43.5 (254) 0.592
Total cholesterol (mmol/L) 3.8 ± 1.1 3.8 ± 1.1 0.59
Triglycerides (mmol/L) 101.3 ± 54.1 101.9 ± 57.9 0.813
BNP (pg/mL) 442.8 [250.5–789.9] 458.6 [259.5–829.3] 0.537
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we found no interactions between treatment and risk factors,
such as diabetes mellitus, hypertension, hypercholesterolemia,
and smoking, or medical history, such as ischemic heart dis-
ease or atrial fibrillation. Also, no significant treatment inter-
action with medication was observed.
Biomarkers
Subgroup analyses across patient groups divided by the median
of the biomarker of interest are summarized in Fig. 2b. In general,
we observed a greater treatment benefit of rolofylline in patients
with elevated levels of most of the biomarkers. We found signif-
icant interactions between treatment and ESAM (p = 0.045),
GDF-15 (p = 0.035), neuropilin (p = 0.001), red blood cell count
(p = 0.004), ST2 (p = 0.002), TNF-R1α (p = 0.028), and uric
acid (p = 0.033) (Fig. 2b), for which rolofylline had a greater
treatment effect in subgroups above the median of the biomarker
of interest.
After this, we studied the heterogeneity in treatment effect
across the continuum of each biomarker.We found a divergent
and consistent STEPP pattern with significant treatment inter-
actions across the continuum of TNF-R1α (p = 0.013), ST-2
(p = 0.016), neuropilin (p = 0.002), WAP-4C (p = 0.002), total
cholesterol (p = 0.019), and potassium (p= 0.025). STEPP plots
for the relative risk of 180-daymortality are shown in Fig. 3. The
absolute 180-day survival percentage and differences for
rolofylline group and placebo group are presented in Fig. S1 of
the Supplementary Material Online.
Fig. 2 a Forest plots of the treatment effect for 180-day all-cause mor-
tality per clinical characteristic. Subgroups were defined by median (if
continuous) or by category (if categorical). No significant interactions
with treatment were observed for subgroups defined by clinical charac-
teristics. Abbreviations: BMI, body mass index; LVEF, left ventricular
ejection fraction; HFPEF, heart failure with preserved ejection fraction;
COPD, chronic obstructive pulmonary disease; ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker; MRA, mineralo-
corticoid receptor antagonist. b Forest plots of the treatment effect for
180-day all-cause mortality per biomarker level. Subgroups were defined
by median. Forest plots demonstrated significant treatment interactions
with ESAM (p = 0.045), GDF-15 (p = 0.035), neuropilin (p = 0.001), red
blood cell count (p = 0.004), ST2 (p = 0.002), TNF-R1α (p = 0.028), and
uric acid (p = 0.033). Abbreviations: ANP, atrial natriuretic peptide; BNP,
brain natriuretic peptide; CRP, C-reactive protein; ESAM, endothelial cell
selective adhesion molecule; GDF-15, growth differentation factor;
LTBR, lymphotoxin beta receptor; NGAL, neutrophil gelatinase-
associated lipocalin; NT-proCNP, N-terminal pro-C-type natriuretic pep-
tide; PIGR, polymeric immunoglobulin receptor; proADM, pro-
adrenomedullin; PSAPB, prosaposin B; RAGE, receptor for advanced
glycation endproducts; TNF-R1a, tumor necrosis factor α receptor-1;
TROY, tumor necrosis factor receptor superfamily member; TnI,
troponine I; ET-1, endothelin 1; IL-6, interleukin 6
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Identifying Responders and Nonresponders to Rolofylline
The concentration where STEPP demonstrated a cross-
over in relative treatment effect was considered as a clini-
cally relevant cut-point. We dichotomized the continuous
levels of these biomarkers at the level of this cut-point.
According to the STEPP plots, the following thresholds
were estimated: TNF-R1α: 4.00 ng/mL; ST2: 5.77 ng/
mL; neuropilin 15.25 ng/mL, WAP-4C 26.92 ng/mL, total
cholesterol 3.93 mmol/L, and potassium 4.1–4.7 mmol/L.
The new factor variables of these dichotomized biomarkers
were then entered in a multivariable Cox regression model.
Multivariable Cox regression modeling yields the follow-
ing β-coefficients: TNF-R1α 0.49, ST-2 0.48, neuropilin
0.05, WAP-4C 0.29, total cholesterol 0.45, and potassium
0.15. Neuropilin and potassium were excluded from the
sum score model, due to their low β-coefficients. The score
sum, including TNF-R1α, ST-2, WAP-4C, and total cho-
lesterol, ranged between 0 and 4 (Table 2). In this score
sum, TNF-R1α ≥ 4.00 ng/mL, ST-2 ≥ 5.77 ng/mL, and
WAP-4C ≥ 26.92 ng/mL received one point, while total
cholesterol ≤3.93 mmol/L received one point. Thus,
TNF-R1α < 4.00 ng/mL, ST-2 < 5.77 ng/mL, and WAP-
4C < 26.92 ng/mL received zero point, while total
Fig. 2 (continued)
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cholesterol >3.93 mmol/L received zero point. Baseline
characteristics of patients per subgroup are summarized
in Table S1, Supplementary Material Online. Proportion
of men, age, serum creatinine, blood urea nitrogen, pres-
ence of anemia, prevalence of diabetes mellitus, smoking,
ischemic heart disease, peripheral vascular disease, atrial
fibrillation, device therapy, and stroke increased with
increasing points. Systolic and diastolic blood pressure,
heart rate, use of angiotensin converting enzyme (ACE)-
inhibitors, creatinine clearance, sodium, hemoglobin, total
cholesterol, and triglycerides decreased with increasing
points. Kaplan-Meier analyses demonstrated that 180-day
mortality increased significantly across increasing points
(log-rank test p < 0.0001, Fig. 4a). In patients with a max-
imum score of four points (those with increased TNF-R1α,
ST2, WAP-4C, and low total cholesterol), treatment with
rolofyllinewas associatedwith improved prognosis (log-rank test
p = 0.018), while in the intermediate score subgroups (1–3),
rolofylline had no effect on outcomes. In patients with a score
0 (those with low TNF-R1α, ST2, WAP-4C, and increased total
cholesterol), treatmentwith rolofyllinewas associatedwithworse
outcome (log-rank test p = 0.002; Fig. 4b–f). The risk of mortal-
ity in each subgroup per point is summarized in Table 3. The
treatment effect of rolofylline was then studied within each sub-
group of sum score by Cox proportional hazard modeling
Table 2 Sum score for response to rolofylline
Plasma biomarker β-coefficient Points
TNF-R1α ≥4.00 ng/mL 0.49 1
ST-2 ≥5.77 ng/mL 0.48 1
WAP-4C ≥26.92 ng/mL 0.29 1
Total cholesterol ≤3.93 mmol/L 0.45 1
Total points 4
Fig. 3 Subpopulation Treatment Effect Pattern Plot analysis of the
treatment effects of rolofylline vs. placebo treatment effect measured by
hazard ratio (<1 rolofylline better than placebo), with corresponding 95%
confidence interval bands. y-axis: hazard ratio, x-axis: subpopulations by
median. a TNF-R1α, tumor necrosis factor receptor 1 alpha levels (ng/
mL) p value = 0.0128; b ST2 levels (ng/mL) p value = 0.0162; c
neuropilin levels (ng/mL) p value = 0.0024. d WAP-4C, WAP four-
disulfide core domain protein HE4 levels (ng/mL) p value = 0.002; e
Total cholesterol (mmol/L) p value = 0.0192. f Potassium (mmol/L) p
value = 0.0252
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(Table 4). In the 4-point subgroup, rolofylline significantly de-
creased mortality compared to placebo (HR 0.61, 95% CI 0.40–
0.92, p = 0.019). In the 1–3-point subgroup, treatment with
rolofylline did not result in differences in survival rate between
the two treatment groups (1 point: HR 1.35, 95% CI 0.76–2.40,
p = 0.306; 2 points: HR 0.74, 95% CI 0.44–1.24, p = 0.249; 3
Fig. 4 a Kaplan-Meier survival curves according to points subgroup.
Unadjusted Kaplan-Meier survival curves according to total points based
on biomarker response score chart. Log rank ≤0.0001. b Unadjusted
Kaplan-Meier estimates of survival in patients with four points, according
to treatment group. Log rank = 0.0178. c Unadjusted Kaplan-Meier esti-
mates of survival in patients with three points, according to treatment
group. Log rank = 0.638. d Unadjusted Kaplan-Meier estimates of sur-
vival in patients with two points, according to treatment group. Log
rank = 0.247. eUnadjusted Kaplan-Meier estimates of survival in patients
with one point, according to treatment. Log rank = 0.304. f Unadjusted
Kaplan-Meier estimates of survival in patients with zero points, according
to treatment. Log rank = 0.0015
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points: HR 1.14, 95% CI 0.67–1.94, p = 0.639). In the 0-point
subgroup, treatment with rolofylline was associated with worse
outcome, compared to the placebo group (HR 5.52, 95% CI
1.68–18.13, p = 0.005). The treatment by score interaction was
statistically significant (treatment by score interaction p < 0.001).
Internal validation by subpopulation bootstrapping estimated
similar hazard ratio estimates (0 points: HR 5.56, 95% CI
5.27–7–5.87; 1 point: HR 1.31, 95% CI 1.25–1.33; 2 points:
HR 0.75, 95% CI 0.74–0.76; 3 points: HR 1.13, 95% CI 1.11–
1.15; 4 points, HR 0.61, 95% CI 0.61–0.62) compared to the
original data.
Discussion
In the current study, we demonstrated that biomarkers may be
used to identify subpopulations with distinct responses to phar-
macological therapy in acute heart failure. We could not demon-
strate interactions between treatment and clinical characteristics,
which underscores the incremental value of biomarkers in ex-
ploring treatment heterogeneity.
Many drugs have been studied to improve clinical outcome
in acute heart failure, but none of them have entered routine
clinical care [2–8]. Randomized controlled studies, considered
to be the golden standard to measure a treatment effect, are
analyzed as a whole, and a study is considered positive if the
treatment effect of the intervention group is superior to the
treatment effect of the control group. However, individual
differences in patient’s clinical characteristics, biomarkers, or
genes may result in a differential response to treatment. This is
especially the case for acute heart failure, as acute heart failure
is a heterogeneous syndrome encompassing patients differing
in disease severity, etiology, and comorbidities. In addition,
acute heart failure patients are often treated with multiple
drugs [13], which multiplies the risk of drug side effects and
drug interactions. Therefore, there is a pressing need for novel
approaches to study treatment heterogeneity, where the ulti-
mate goal is to develop tools to identify groups of apparently
clinically homogeneous patients but with a distinct response
to acute heart failure treatment.
Subgroup analyses are necessary to identify subpopula-
tions that differ in their response to treatment. Subgroups are
often defined by clinical characteristics; however, convention-
al subgroup analysis based on clinical demographics often
failed to demonstrate any differences in treatment effect.
Circulating biomarkers however may provide more accurate
information regarding related individual biological interac-
tions influencing therapeutic response [14]. This utility would
take biomarkers beyond their current role as a diagnostic or
prognostic marker. A few studies have already illustrated the
potential role of a single biomarker in determining drug re-
sponse and treatment monitoring in heart failure [15]. ACE-
inhibitors, for instance, were more effective in patients with
high pre-treatment plasma renin activity [16, 17]. Also, it is
hypothesized that tolvaptan may be more effective in patients
with high copeptin levels, which is currently under investiga-
tion in the Acute Heart Failure Patients With High Copeptin
Treated With Tolvaptan Targets Increased AVPActivation for
Treatment (ACTIVATE, NCT01733134) trial.
In the current study, we used a novel approach to iden-
tify subgroups with distinct responses to rolofylline in
acute heart failure. Although forest plots are generally
accepted as a useful graphical method of displaying treat-
ment effects across subgroups, this and other conventional
subgroup analyses require dividing study population into
spurious and incoherent subgroups, such as median or
quartiles, which are not necessarily clinical relevant, and
are, furthermore, associated with statistical concerns
[18–21]. Also, such disjoint dividing of the study popula-
tion decreases the predictive value of a continuous vari-
able. As few patients or events may be represented in a
subgroup, it may also increase the risk of false negative
results, thus reducing the power to calculate the individual
estimates of a treatment effect. STEPP is an exploratory
graphical statistical method [10, 11] that allows studying
heterogeneity of treatment across the continuous level of a
covariate, in our case, a biomarker. This approach avoids
the demand of dividing the study population into non-
sense subgroups and allows the investigator to explore
clinically relevant cut-points. In addition, STEPP analyses
treatment effect in overlapping subpopulations, increases
the precision of treatment estimates, making STEPP a
Table 4 The efficacy of rolofylline per point subgroups
Total points Hazard ratio 95% confidence interval p value
0 5.52 1.68–18.13 0.005
1 1.35 0.76–2.40 0.306
2 0.74 0.44–1.24 0.249
3 1.14 0.67–1.94 0.639
4 0.61 0.40–0.92 0.019
Table 3 Hazard ratio of 180-day mortality across point subgroups
Total points Hazard ratio 95% confidence interval p value
0 Reference group
1 1.17 0.76–1.80 0.482
2 1.69 1.10–2.60 0.017
3 2.38 1.56–3.63 <0.001
4 4.81 3.11–7.19 <0.001
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more accurate, robust, and reliable statistical method to
determine treatment heterogeneity.
In our study, we first studied differential response
across clinical characteristics by forest plots. Forest plots
did not reveal any interaction between clinical character-
istics and rolofylline. This finding is in line with that of
previous subgroup analyses of the PROTECT study pop-
ulation on the primary endpoint, 60-day death or cardio-
vascular or renal hospitalization and persistent renal im-
pairment, showing no treatment heterogeneity across clin-
ical characteristics [7, 9]. In contrast to clinical character-
istics, we found significant interactions between treatment
and several biomarkers with both forest plots and STEPP.
Interestingly, we did not observe any tendency to a profile
of clinical characteristics that may be associated with re-
sponse to rolofylline based on the results of the forest
plots, but we found a consistency in the interaction pat-
tern of biomarkers studied by forest plots, i.e., higher
levels of the majority of the measured biomarkers were
related to a better treatment response to rolofylline. Since
higher levels of these biomarkers indicated patients at
higher risk, we suggest that rolofylline might have been
more effective in patients at higher clinical risk, while it
might have been harmful in the lower risk patients.
Indeed, patient characteristics of each subgroup differ:
patients with zero points were more likely to be younger
and female and have higher blood pressure and heart rate,
less diabetes and a history of ischemic heart disease, ane-
mia, and renal dysfunction; whereas, patients with four
points were more likely to be older and men and have
lower blood pressures and heart rate, diabetes, ischemic
heart disease, anemia, and renal dysfunction. Although we
demonstrated that the responder and nonresponder sub-
groups differ in baseline characteristics, subgroup analy-
ses across these characteristics did not demonstrate any
interaction with treatment, emphasizing the additive value
of biomarkers in studying differential reponse.
With STEPP, we were able to establish a clinically
relevant cut-point, rather than to study dichotomized bio-
markers at an arbitrary cut-point level (median). We de-
veloped a simple sum score to identify subgroups of pa-
tients with distinct responses to treatment. Internal valida-
tion demonstrated similar results compared to the original
data. It needs to be emphasized that we were not able to
perform an external validation of our results, and there-
fore, our results should be interpreted with caution. The
present analysis was only deemed to explore the differen-
tiating and incremental value of biomarkers in studying
treatment heterogeneity. Therefore, we cannot conclude
that these six biomarkers are the unique biomarker set that
predicts treatment response to rolofylline. An additional interest-
ing observation was the consistency of higher levels of the ma-
jority of the measured biomarkers to be related to a better
treatment response to rolofylline. Since higher levels of these
biomarkers indicated patients at higher risk, we suggest that
rolofylline might have been more effective in patients with high
clinical risk, while it might have been harmful in lower risk
patients. This hypothesis was separately evaluated and confirmed
in a recently published paper by Demissei et al. using the same
cohort [22]. Baseline risk of 180-day all-cause mortality was
calculated by a previously published model that combined both
clinical characteristics and biomarkers [23]. In patients in low- to
intermediate-risk subgroups, rolofylline was associated with a
higher rate of 180-day all-cause mortality (11.9% in the
rolofylline versus 8.4% in the placebo arms, p = 0.050). In the
high-risk subgroup of patients, particularly those with estimated
risk of mortality between 20 and 30%, 180-day all-cause mortal-
ity rate was markedly lower in the rolofylline arm (18.4% in the
rolofylline versus 34.0% in the placebo arms, p = 0.003). The
trend towards potential harm with rolofylline treatment in the
low- to intermediate-risk subpopulations and the significant ben-
efit in high-risk patients were also observed in the PROTECT
pilot trial that served as a validation cohort [24].
The present study has several limitations. In addition to
the disadvantage of post hoc analyses, our study did not
include an external validation cohort, and repeated testing
on the same data results in inflation of the α-levels and
thereby increases the risk of finding false-positive results.
Therefore, these results should be considered as explor-
ative and should be interpreted with caution. In addition,
we studied all available established and novel emerging
biomarkers of the current dataset. We did not select bio-
markers based on the clinical relevancy and plausible as-
sociations with the study drug.
In summary, biomarkers may be used to identify sub-
populations with distinct treatment response in acute heart
failure. Exploring biomarker-treatment interactions may
be a selective approach to distinguish in advance those
patients who may benefit from treatment from those who
will most likely suffer harm without gaining benefit in
acute heart failure. Future drug development programs
could benefit from incorporating such an approach to
match the right patient to the study drug, serving the ul-
timate goal to customize therapy for each individual
patient.
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